कोशिश गोल्ड - मुक्त

Bio Spectrum - December 2025

मैगज़्टर गोल्ड के साथ असीमित हो जाओ

पढ़ना Bio Spectrum केवल एक सदस्यता के साथ 10,000+ अन्य पत्रिकाएँ और समाचार पत्र

कैटलॉग देखें

1 महीना

$14.99

1 वर्ष $149.99

$149.99

$12/month

(OR)

केवल Bio Spectrum की सदस्यता लें

उपहार Bio Spectrum

किसी भी समय रद्द करें.

(कोई प्रतिबद्धता नहीं) ⓘ

यदि आप सदस्यता से खुश नहीं हैं, तो आप पूर्ण धनवापसी के लिए सदस्यता आरंभ तिथि से 7 दिनों के भीतर हमें help@magzter.com पर ईमेल कर सकते हैं। कोई प्रश्न नहीं पूछा जाएगा - वादा! (नोट: एकल अंक खरीद के लिए लागू नहीं)

डिजिटल सदस्यता

त्वरित पहुँच ⓘ

मैगज़टर वेबसाइट, आईओएस, एंड्रॉइड और अमेज़ॅन ऐप पर तुरंत पढ़ना शुरू करने के लिए अभी सदस्यता लें।

सत्यापित सुरक्षित

भुगतान ⓘ

मैगज़्टर एक सत्यापित स्ट्राइप व्यापारी है।

इस अंक में

TRENDS 2026: Rise of RESILIENT Life Sciences Innovation
US President Donald Trump’s tariffs, with a fear of global recession and geopolitical tensions affecting industries worldwide, was the memorable aspect of 2025. Despite these challenges, the Indian life sciences sector has remained resilient and steadfast. To avoid the impact of Trump's tariffs, almost all major pharma firms expanded or increased their presence in the US, often through acquisitions. A key highlight was the Indian government introducing several measures to simplify drug approvals and support innovation. Key reforms included updating the New Drug and Clinical Trial Rules (2019) and adopting digital platforms for regulatory submissions to improve transparency, reduce approval timelines, strengthen pharmacovigilance, and maintain quality standards. As we move into 2026, many of the trends and themes from 2025 are expected to carry forward, shaping the industry’s trajectory in the year ahead. Let’s look at these trends across different sectors.

Re-Pivoting Pharma Strategy

The United States has effectively shut the door on several Indian medicines after President Donald Trump imposed a steep 100 per cent duty on branded and patented drugs. The tariff, effective from October 1, triggered trade and policy uncertainty across the global pharmaceutical industry. Till then, medicines had largely been spared from the Trump administration's tariff regime. The abrupt move forced drug exporters to the US to rethink their strategies. India, however, remained insulated to some extent because of the nature of its export basket and presence of manufacturing units of some Indian companies in the US.

2 mins

Telangana targets Rs 1 lakh crore investments in Life Sciences by 2030

Telangana has set an ambitious target of attracting Rs 1 lakh crore in new investments in the Life Sciences sector by 2030, aiming to generate employment for five lakh people, as per Minister for IT and Industries Duddilla Sridhar Babu.

1 mins

ANRF, in collaboration with ICMR and Gates Foundation, launches Maha MedTech Mission

Anusandhan National Research Foundation (ANRF), in collaboration with the Indian Council of Medical Research (ICMR) and the Gates Foundation, has launched the Mission for Advancement in High-Impact Areas (MAHA)-Medical Technology (hm MedTech).

1 mins

Karnataka unveils Rs 600+ Cr 'Deep Tech Decade' initiative

The Government of Karnataka has announced an investment of over Rs 600 crore to power the state's \"Deep Tech Decade,\" with the goal of establishing Karnataka as the Deep Tech Capital of India.

1 mins

Siegwerk makes entry into pharma packaging segment in India with Rs 350 Cr investment

German firm Siegwerk has announced its strategic entry into the pharmaceutical packaging segment in India, reinforcing its commitment to consumer safety.

1 mins

MedGenome makes majority investment in Gujarat's Green Cross

Bengaluru-based MedGenome, a leading global genomics-driven diagnostics and research services company, has announced a majority investment in Gujarat-headquartered pathology laboratory chain, Green Cross Genetics Lab.

1 mins

Remidio unveils breakthrough in AI-enabled.retinal imaging for newborns

Bengaluru-based Remidio Innovative Solutions, a leader in artificial intelligence (AI)-powered ophthalmic devices, has announced the launch of Neubo 130, a next-generation ultra-widefield neonatal retinal imaging system designed to enhance precision diagnostics for neonatal retinal conditions like Retinopathy of Prematurity (ROP).

1 mins

Bharat Biotech launches Nucelion, CRDMO arm to focus on next-gen cell and gene therapy

Bharat Biotech International Ltd, announced the launch of Nucelion Therapeutics, a Contract Research Development and Manufacturing Organisation (CRDMO) focused on cell and gene therapies as its wholly owned subsidiary in Hyderabad.

1 mins

Alkem Foundation and IIT-B to set up advanced research centre for immuno- therapeutics and regenerative medicines

Alkem Foundation, the Corporate Social Responsibility (CSR) arm of Mumbai-based Alkem Laboratories, and Indian Institute of Technology Bombay (IIT-B) have announced a strategic collaboration to set up a first- of-its-kind research centre in India dedicated to immuno- therapeutics and regenerative medicines.

1 mins

Philips and Nicolab collaborate to advance stroke care in India

Dutch firm Philips is expanding its collaboration with Nicolab, The Netherlands-based company pioneering in artificial intelligence (AI)-powered stroke care, to advance stroke care in India.

1 mins

Biocon Biologics and Civica expand partnership to launch private-label insulin glargine in US

Bengaluru-based Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., has announced expansion of its strategic collaboration with Civica, Inc. to include a new Insulin Glargine medicine that will benefit patients in the United States by increasing supply of high-quality affordable insulins.

1 mins

Shilpa Medicare opens flow chemistry manufacturing centre in Bengaluru

Shilpa Medicare, a full-service contract development and manufacturing organisation (CDMO), has announced the launch of its new flow chemistry Centre of Excellence (CoE).

1 mins

DPIIT signs MoU with Primus Partners to strengthen startup ecosystem

The Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry, Government of India, has signed a Memorandum of Understanding (MoU) with Primus Partners to enhance collaboration towards strengthening India's startup and innovation ecosystem.

1 mins

Bessemer Venture Partners leads Rs 125 Cr Series A funding in fertility startup Pluro

Pluro Fertility and IVF, a healthcare partnership platform, has raised Rs 125 crore in Series A funding round led by Bessemer Venture Partners at a valuation of Rs 1,000 crore.

1 mins

DPIIT signs MoU with Primus Partners to strengthen startup ecosystem

The Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry, Government of India, has signed a Memorandum of Understanding (MOU) with Primus Partners to enhance collaboration towards strengthening India's startup and innovation ecosystem.

1 mins

Helex raises $3.5 M to advance targeted gene therapies for kidney diseases

Helex, a US and India-based therapeutics startup developing a new class of targeted medicines for genetic kidney diseases, has announced its oversubscribed $3.5 million Seed round, led by pi Ventures.

1 mins

Qure.ai launches world's first AI-powered paediatric TB screening tool

Diagnosing tuberculosis (TB) in children has long been a challenge, but that is set to change. qXR from Mumbai-based startup Qure.ai is the first AI-enabled chest X-ray tool to receive regulatory clearance, earning CE Class IIb certification for children aged 0-3 years and complementing its existing capabilities for children up to 15 years, effectively covering the entire childhood spectrum.

1 mins

C-CAMP signs MoU with NIMHANS to launch Centre for Bioentrepreneurship in Neurosciences and Mental Health

Bengaluru-based Centre for Cellular and Molecular Platforms (C-CAMP) and the National Institute of Mental Health and Neurosciences (NIMHANS), an institute of national importance, and the India’s largest public sector research organisation in mental health and neuroscience, have joined hands to set up a unique initiative – the Centre for Bioentrepreneurship in Neurosciences and Mental Health.

1 mins

Bartronics India makes strategic investment of up to Rs 50 Cr in Huwel Life Sciences

Hyderabad-based Bartronics India Limited (BIL), a listed technology and services company, has announced a strategic investment of up to Rs 50 crore in Huwel Life Sciences, a molecular diagnostics startup, also based in Hyderabad.

1 mins

TRENDS 2026: Rise of RESILIENT Life Sciences Innovation

US President Donald Trump's tariffs, with a fear of global recession and geopolitical tensions affecting industries worldwide, was the memorable aspect of 2025. Despite these challenges, the Indian life sciences sector has remained resilient and steadfast. To avoid the impact of Trump's tariffs, almost all major pharma firms expanded or increased their presence in the US, often through acquisitions. A key highlight was the Indian government introducing several measures to simplify drug approvals and support innovation. Key reforms included updating the New Drug and Clinical Trial Rules (2019) and adopting digital platforms for regulatory submissions to improve transparency, reduce approval timelines, strengthen pharmacovigilance, and maintain quality standards. As we move into 2026, many of the trends and themes from 2025 are expected to carry forward, shaping the industry's trajectory in the year ahead. Let's look at these trends across different sectors.

9 mins

How India's Diabetes Crisis is Driving Med Devices Market

A growing diabetic population in India is a blessing for the care devices market. Both Indian and global diabetes care devices have taken this growing demand for various devices, kits as an opportunity to expand their market share. But the scope in rural areas seems a bit challenging for various companies due to less awareness about the disease, affordability etc. Let's look at this growing diabetes care devices market.

9 mins

Converging MedTech with Affordability in 2026

On October 25, the Anusandhan National Research Foundation (ANRF) launched the Mission for Advancement in High-Impact Areas (MAHA)-Medical Technology, in collaboration with the Indian Council of Medical Research (ICMR) and the Gates Foundation. With an objective to accelerate innovation in India's medical technology sector, reduce reliance on high-cost imports, and promote equitable access to affordable and high-quality medical technologies, new doors are opening up for the MedTech sector in 2026, with greater emphasis on startups. Let's take a close look at how the MedTech startups are redefining India's innovation ecosystem.

4 mins

India's Strategic Shift Towards High-Quality, Low-Cost MedTech

India's healthcare infrastructure continues to face significant strain from the rising prevalence of noncommunicable diseases (NCDs), contributing around 66 per cent of the mortalities in the country, underscoring the need for scalable continuous monitoring, early diagnosis, and therapeutic devices. Yet, advanced imaging systems, analysers, surgical tools, or robotic devices remain very expensive due to import reliance, high logistics costs, and maintenance/service contracts. Segments showing strongest traction today are diagnostics (point-of-care devices, rapid tests, compact imaging devices), remote monitoring/wearable devices, and therapeutic devices such as surgical robotic systems, renal care systems, and wound care devices.

4 mins

'Despite global funding slowdowns, India's early-stage healthcare scene, especially in digital health and diagnostics, remains strong'

US-based Illumina Inc., a global leader in DNA sequencing and array-based technologies, established its presence in India nearly 20 years ago, laying the foundation for a strong role in the country's genomics ecosystem. At present, Illumina is driving early cancer detection in India by advancing comprehensive genomic profiling and enabling liquid biopsy technologies. With new expansion plans in place, Illumina is all set to further strengthen India's genomics landscape. In an exclusive interaction with BioSpectrum India, Suchita Dayanand, Country Head – India (Commercial), Illumina shares her plans. Edited excerpts;

4 mins

"India has the talent and ambition to lead globally in advanced therapies, biologics, and oncology"

Thermo Fisher Scientific has recently announced plans to make significant investments in India's biopharma infrastructure, with new facilities that will enhance the biopharma manufacturing capabilities. Central to this expansion strategy are two major facilities in Genome Valley, Hyderabad, i.e. Bioprocess Design Center (BDC), and Customer Experience Center (CEC). In addition, the company has invested more than Rs 160 crore this year to expand its R&D facility in Bengaluru. For further understanding on these new developments, BioSpectrum spoke in detail to Srinath Venkatesh, Managing Director, India & South Asia, Thermo Fisher Scientific. Edited excerpts;

4 mins

"India can become a global hub for AI-driven diagnostics if right policy environment is in place"

With India emerging as the fourth largest medical devices market in Asia after Japan, China, and South Korea, the Indian medical technology sector is being recognised as a sunrise sector because of its immense growth potential driven by the country's increasing healthcare needs, technological innovations, government support, and emerging market opportunities. The size of the Indian medical devices sector is estimated to be around $14 billion and it is expected to grow to $30 billion by 2030 where artificial intelligence (AI) is bound to play a major role. Amidst this scenario, Japan's medtech player Fujifilm is uniquely positioning it's presence to meet India's growing healthcare demands, blending AI, advanced imaging, and affordable solutions. In an exclusive interaction with BioSpectrum Asia, Koji Wada, Managing Director (Healthcare Division), Fujifilm India spoke about the company's expansion plans in India.

4 mins

"AI is a transformative enabler that's reshaping how science is conducted in labs"

2025 witnessed multiple new initiatives taken by Agilent Technologies, a global leader in life sciences, diagnostics, and applied chemical markets, for the Indian market. These initiatives included establishment of an India Solutions Center in Manesar; and a Biopharma Experience Center in Hyderabad. 2025 also saw Nandakumar Kalathil stepping in as the new Country General Manager for Agilent India. With over 25 years of experience in the analytical industry, Nanda brings extensive expertise in leadership, team management, and customer relations. To find out more about the company's growth plans in 2026 in India, BioSpectrum interacted with Nandakumar Kalathil, Country General Manager for Agilent India in detail. Edited excerpts:

4 mins

How AI is Redefining Talent and Innovation in Life Sciences

AI's future in life sciences will be driven by hybrid expertise, continuous upskilling, and strong collaboration across academia, industry, and clinical practice to build a smarter, more responsive healthcare ecosystem.

5 mins

BTS 2025 Solidifies Karnataka's Global Tech Leadership

The 28th edition of the Bengaluru Tech Summit (BTS) 2025 concluded on November 20 at the Bangalore International Exhibition Centre (BIEC), wrapping up three days of high-impact innovation, global collaboration, and technology leadership.

3 mins

Monash University Malaysia and Tata Chemicals forge healthcare researchfocused partnership

The importance of gastrointestinal health is a key focus for researchers and innovators, as highlighted by the partnership between Monash University Malaysia and Tata Chemicals Limited.

1 mins

Cabinet approves major expansion of PG and UG medical education capacity

Union Cabinet chaired by the Prime Minister Narendra Modi has approved the Phase-Ill of the Centrally Sponsored Scheme (CSS) for strengthening and upgradation of existing State Government/ Central Government Medical Colleges/Standalone PG Institutes/ Government Hospitals for increasing 5,000 PG seats and extension of the CSS for upgradation of existing government medical colleges for increasing 5,023 MBBS seats with an enhanced cost ceiling of Rs 1.5 crore per seat.

1 mins

Ayush Ministry announces SPARK-4.0 to nurture young ayurveda researchers

The Central Council for Research in Ayurvedic Sciences (CCRAS), Ministry of Ayush, has announced SPARK-4.0 (2025-26)—the fourth edition of its flagship Studentship Programme for Ayurveda Research Ken (SPARK).

1 mins

Dr Sharvil Patel steps in as Indian Pharmaceutical Alliance President

The Indian Pharmaceutical Alliance (IPA) has announced a leadership transition, with Dr Sharvil Patel, Managing Director of Zydus Lifesciences and former Vice President of IPA, assuming the role of President.

1 mins

Motorica strengthens India presence with appointment of Kavinder Beniwal as COO

Motorica, a Delhi-based medtech company specialising in assistive technologies and medical cybernetics, has announced the appointment of Kavinder Beniwal as Chief Operational Officer (COO) of Motorica India.

1 mins

Sanofi India appoints Deepak Arora as new Managing Director

Pharma major Sanofi India has appointed Deepak Arora as the company's Managing Director with effect from October 27, 2025. In this role, Arora will define and drive the strategic vision for India in alignment with Sanofi's global strategy.

1 mins

Plasmagen Biosciences onboards Vivek V Kamath as Chief Executive Officer

Bengaluru-based Plasmagen Biosciences, a biopharmaceutical company focused on blood plasma-derived pharmaceutical products for India and emerging markets, has announced the appointment of Vivek V Kamath as its Chief Executive Officer. Kamath brings over three decades of leadership experience in healthcare, spanning pharmaceuticals, over-the-counter (OTC) products and diagnostics.

1 mins

Veteran policy maker & former IRDAI Chairman Debasish Panda joins Pristyn Care

Debasish Panda, former Chairman of the Insurance Regulatory and Development Authority of India (IRDAI) has taken on the role of Senior Advisor to Pristyn Care.

1 mins

PAG-led Sekhmet Pharmaventures announces appointment of Mukesh Agarwal as CFO

Hyderabad-based Sekhmet Pharmaventures, a fast-emerging global API/CDMO player led by leading Asia-focused investment firm PAG, has announced the appointment of Mukesh Agarwal as its new Chief Financial Officer (CFO).

1 mins

Supporting India's Biopharma Expansion with Advanced, High-Performance Media

Kent Wang graduated from East China University of Science and Technology in Biochemical Engineering. He has over 12 years of experience in upstream biopharmaceutical process development, contributing to clinical projects including monoclonal antibodies, bispecific antibodies, and ADCs. He is well-versed in CHO cell metabolism and culture media characteristics, and has optimized critical quality attributes such as glycosylation, charge variants, fragmentation, aggregation, and amino acid oxidation. Previously at Shanghai Pharmaceuticals Group and 3S Bio, he now serves as Senior R&D Director at Duoning Biotech, focusing on serum-free cell culture media development. He established a comprehensive platform for media formulation and product development, leading his team to create a diverse portfolio of media for CHO, HEK293, insect, vaccine, hybridoma, and lymphocyte cell lines, leveraging cell metabolism insights and big data modeling.

4 mins

Aber and Sartorius unveil BioPAT Viamass single-use biomass sensors

Aber Instruments and Sartorius Stedim Biotech have announced the introduction of the BioPAT Viamass single-use biomass sensor now fully integrated into Ambr 250 High Throughput single-use bioreactor vessels.

1 mins

Thermo Fisher Scientific invests Rs 160 Cr+ to expand Bengaluru R&D facility

Thermo Fisher Scientific's expanded Research and Development (R&D) Centre of Excellence was inaugurated in Bengaluru by Sanjeev Kumar Gupta, CEO, Karnataka Digital Economy Mission (KDEM).

1 mins

VFL Sciences launches lab photobioreactors GreatFlo PBR

Chennai-based VFL Sciences has announced the launch of GreatFlo PBR, laboratory Photo Bioreactors during the IKMC 2025 exhibition at Hyderabad. VFL Sciences Photo Bioreactors have been designed with focus on customers to deliver a state-of-the-art instrument that fits comfortably on a lab bench.

1 mins

Corning and SGD Pharma inaugurate glass tubing facility in Telangana for pharma packaging

Corning Inc and SGD Pharma have announced the inauguration of a new glass tubing facility in Telangana, which will expand pharmaceutical manufacturing in the region.

1 mins

Revvity and Profluent bring AI-enhanced adenine deaminase pin-point base editing systems

US-based Revvity, Inc. has announced a strategic collaboration with Profluent, also based in the US, bringing together a range of its novel artificial intelligence (AI)engineered enzymes with Revvity's established Pin-point base editing platform.

1 mins

Agilent introduces Altura Line of Inert HPLC columns for biotherapeutic testing

Agilent Technologies Inc. has announced the release of a new range of high performance liquid chromatography (HPLC) columns ideally suited for biotherapeutics applications.

1 mins

AI Becomes Pharma's Powerhouse in 2025

As we wrap up 2025, we take a close look at the major developments that took place across the globe, including India, within the artificial intelligence (AI)-driven drug discovery segment. Highlighting one of the most recent announcements, US-based pharma major Eli Lilly has partnered with NVIDIA to build the industry's most powerful AI supercomputer, supercharging medicine discovery.

2 mins

सभी कहानियाँ पढ़ें Bio Spectrum

Bio Spectrum Description:

प्रकाशक: MM-Activ-Sci-Tech-Communication

वर्ग: Business

भाषा: English

आवृत्ति: Monthly

India's leading publication that covers the business of bio-technology. With comprehensive analyses of policy issues, products and services across the bio-pharma, bio-informatics, bio-infrastructure and bio-agriculture segments, it is the industry's most authoritative source of information.